Journey Medical Corp [DERM] stock is trading at $8.01, down -4.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The DERM shares have gain 10.18% over the last week, with a monthly amount glided 1.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Journey Medical Corp [NASDAQ: DERM] stock has seen the most recent analyst activity on August 25, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $13. On August 22, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $9 on the stock. B. Riley Securities initiated its recommendation with a Buy and recommended $14 as its price target on December 07, 2021.
Journey Medical Corp [DERM] stock has fluctuated between $3.54 and $9.40 over the past year. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Journey Medical Corp [NASDAQ: DERM] shares were valued at $8.01 at the most recent close of the market. An investor can expect a potential return of 62.3% based on the average DERM price forecast.
Analyzing the DERM fundamentals
Journey Medical Corp [NASDAQ:DERM] reported sales of 59.40M for the trailing twelve months, which represents a growth of 20.52%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.4 and Total Capital is -0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.98.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Journey Medical Corp’s Current Ratio is 1.42. On the other hand, the Quick Ratio is 1.12, and the Cash Ratio is 0.63. Considering the valuation of this stock, the price to sales ratio is 4.48, the price to book ratio is 8.16.
Transactions by insiders
Recent insider trading involved Maraoui Claude, President & CEO, that happened on May 02 ’25 when 4834.0 shares were sold. CFO, Benesch Joseph completed a deal on May 02 ’25 to sell 2409.0 shares. Meanwhile, COO Alloush Ramsey sold 2857.0 shares on May 02 ’25.
